Structure Therapeutics GPCR
$16.13 −$0.99 (-5.78%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $16.69 +3.47%
Open$16.73
Prev close$17.12
Day range$16.06 – $17.08
Volume786.2K
Market cap$1.15B
P/E (TTM)–
Dividend yield–
GPCR Stock News
Headlines matching Structure Therapeutics or the GPCR ticker, most recent first.
- Canaccord Genuity Remains a Buy on Structure Therapeutics, Inc. Sponsored ADR (GPCR)
- CCORF Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $111
- H.C. Wainwright Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $70
- Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR), Belite Bio, Inc. ADR (BLTE) and BridgeBio Oncology Therapeutics (BBOT)
- Analysts Are Bullish on These Healthcare Stocks: EnGene Holdings (ENGN), Structure Therapeutics, Inc. Sponsored ADR (GPCR) Positive
- A Quick Look at Today's Ratings for Structure Therapeutics(GPCR.US), With a Forecast Between $70 to $125
- A Quick Look at Today's Ratings for Structure Therapeutics(GPCR.US), With a Forecast Between $70 to $111
- Jefferies Remains a Buy on Structure Therapeutics, Inc. Sponsored ADR (GPCR)
- A Quick Look at Today's Ratings for Structure Therapeutics(GPCR.US), With a Forecast Between $97 to $145
- J.P. Morgan Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Announces Target Price $100
- Morgan Stanley Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $126
- Analysts Have Conflicting Sentiments on These Healthcare Companies: Oculis Holding (OCS), Stevanato Group (STVN) and Structure Therapeutics, Inc. Sponsored ADR (GPCR)
- Citi Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $97
- XTALPI: VOLUNTARY ANNOUNCEMENTSTRATEGIC PARTNERSHIP WITH A LEADING BIOPHARMA COMPANYTO DEVELOP ORAL SMALL MOLECULE THERAPEUTICSFOR A GPCR TARGET, WITH A TOTAL POTENTIAL DEAL VALUE OFOVER US$400 MILLION Positive
- J.P. Morgan Maintains Structure Therapeutics(GPCR.US) With Buy Rating
No comments yet — be the first to weigh in on GPCR.
Sign in to join the discussion.